GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Tolvaptan (Samsca), oral tablet

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Samsca - labeled renal guidance

Product / population
Tolvaptan (Samsca), oral tablet
Renal method
Creatinine clearance (CrCl), mL/min
Source revision
DailyMed SPL version 23, posted Jun 01, 2026
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Samsca - product and source limitations

Anuria is a contraindication. Apply the hyponatremia product's hospital initiation and sodium-monitoring instructions.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Samsca - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Tolvaptan (Samsca), oral tablet

Renal method: Creatinine clearance (CrCl), mL/min
Source date: DailyMed SPL version 23, posted Jun 01, 2026
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.7 Use in Patients with Renal Impairment

CrCl below 10 mL/min is an unstudied range in which tolvaptan's sodium effect is likely lost. The label recommends against use there. Anuria is a contraindication. Apply the hyponatremia product's hospital initiation and sodium-monitoring instructions.

RDM74-samsca-official-1 · Source locator: Renal guidance: 8.7 Use in Patients with Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5526617c-c7b9-4556-886d-729bbabbc566
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min
Source date/version
DailyMed SPL version 23, posted Jun 01, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
e7b511c5cd958628038415d5e9ec57b73ef37dd88cfd644c641310d7b99bfb3c

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-samsca&s1=RDM74-samsca-official&h1=14a37692526e4a3f861d9667788fd23b3aa3b9a23189b58c276ef9b13d0c2125

Top